Search results
Found 7185 matches for
PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.
Sir Andrew Pollard
BSc MBBS PhD (Lond), DIC, MRCP (UK), FHEA, FRCPCH, MA, FMedSci, FRS Sir Andrew Pollard - Ashall Professor of Infection & Immunity
Yama G.Farooq
BCA Computer Application , MSc in Information Technology and Software Engineering Yama G.Farooq - Programming and Data Management Director